SCHEMBL1554908

SCHEMBL1554908

COC(CNCCCC(=O)OC(C)(C)C)OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.40
TSHR P16473 2/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
STING1 Q86WV6 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
CTSK P43235 2/20 0.32
CYP2D6 P10635 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
FPR3 P25089 1/20 0.32
FPR2 P25090 1/20 0.32
MLYCD O95822 1/20 0.32
DGAT1 O75907 1/20 0.32
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31226873 0.82 EPHX2 (0.44) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL4537996 0.82 EPHX2 (0.41) EPHX2MAOAMAOBMEN1GAA
SCHEMBL7285688 0.80 CA2 (0.37) MAOAMAOBMEN1GAAKMT2A
SCHEMBL25525668 0.78 MAOA (0.42) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL9891443 0.78 MAOA (0.46) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL20674794 0.78 EPHX2 (0.41) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL25493115 0.77 KDM4E (0.41) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL26207801 0.76 TDP1 (0.47) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL6347343 0.76 PAOX (0.44) EPHX2TSHRMAOAMAOBMEN1
SCHEMBL25400876 0.75 TSHR (0.38) EPHX2TSHRMAOAMAOBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491022-B1 DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS HOFFMANN LA ROCHE (CH) 2014-12-31 EP disclosed
US-8445674-B2 Heterocyclyl compounds Hoffmann-La Roche Inc (US) 2013-05-21 US disclosed
EP-2491022-A1 DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS F. Hoffmann-La Roche AG (CH) 2012-08-29 EP disclosed
WO-2011048032-A1 DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-28 WO disclosed
US-20110092698-A1 NOVEL HETEROCYCLYL COMPOUNDS F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092698-A1 NOVEL HETEROCYCLYL COMPOUNDS CCR2, CCR3, CCR1 EPHX2 1356/4885TSHR 652/4885MAOA 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.